News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US Jury’s Neurontin Ruling To Cost Pfizer Inc. $142 Million
March 26, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Philadelphia Inquirer -- Pfizer Inc. was found by a jury yesterday to have committed racketeering fraud in the marketing of its epilepsy drug Neurontin and must pay $142.1 million in damages.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Vaccines
CDC Formally Adopts Delayed Hepatitis B Vaccine Dose
December 17, 2025
·
4 min read
·
Tristan Manalac
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
December 17, 2025
·
3 min read
·
Jennifer Smith-Parker
Vaccines
Pfizer CEO Blasts HHS’ Anti-Vaccine Policies as Revenue Outlook Dims
December 16, 2025
·
3 min read
·
Annalee Armstrong
Regulatory
Absence of Bureaucracy at FDA Is Shooting Pharma in the Foot
December 12, 2025
·
4 min read
·
Dan Samorodnitsky